SVRA Savara Inc
Price (delayed)
$3.01
Market cap
$519.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.48
Enterprise value
$531.12M
Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management
Highlights
Savara's equity has increased by 22% YoY but it has decreased by 14% from the previous quarter
SVRA's net income has plunged by 75% YoY and by 16% from the previous quarter
The company's EPS fell by 45% YoY and by 14% QoQ
Key stats
What are the main financial stats of SVRA
Market
Valuations
Earnings
Shares outstanding
172.63M
Market cap
$519.63M
Enterprise value
$531.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.01
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$103.2M
Net income
-$95.88M
EBIT
-$95.88M
EBITDA
-$95.61M
Free cash flow
-$89.11M
Per share
Balance sheet
Liquidity
EPS
-$0.48
EPS diluted
-$0.48
Free cash flow per share
-$0.45
Book value per share
$1
Revenue per share
$0
TBVPS
$1.07
Total assets
$212.88M
Total liabilities
$41.43M
Debt
$26.62M
Equity
$171.45M
Working capital
$187.41M
Debt to equity
0.16
Current ratio
13.73
Quick ratio
13.33
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51.2%
Return on equity
-64.5%
Return on invested capital
-52.5%
Return on capital employed
-48.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SVRA stock price
How has the Savara stock price performed over time
Intraday
5.24%
1 week
11.48%
1 month
20.88%
1 year
-35.55%
YTD
-1.95%
QTD
8.66%
Financial performance
How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$103.2M
Net income
-$95.88M
Gross margin
N/A
Net margin
N/A
SVRA's net income has plunged by 75% YoY and by 16% from the previous quarter
Savara's operating income has plunged by 72% YoY and by 15% from the previous quarter
Growth
What is Savara's growth rate over time
Valuation
What is Savara stock price valuation
P/E
N/A
P/B
3.01
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 45% YoY and by 14% QoQ
The stock's price to book (P/B) is 35% less than its last 4 quarters average of 4.4 but 19% more than its 5-year quarterly average of 2.4
Savara's equity has increased by 22% YoY but it has decreased by 14% from the previous quarter
Efficiency
How efficient is Savara business performance
SVRA's return on assets is down by 43% year-on-year and by 10% since the previous quarter
SVRA's ROE is down by 39% YoY and by 10% from the previous quarter
Savara's ROIC has decreased by 37% YoY and by 9% from the previous quarter
Dividends
What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SVRA.
Financial health
How did Savara financials performed over time
SVRA's quick ratio is down by 22% from the previous quarter and by 13% YoY
SVRA's current ratio is down by 22% since the previous quarter and by 12% year-on-year
The debt is 84% smaller than the equity
The debt to equity has grown by 23% from the previous quarter but it has contracted by 16% YoY
Savara's equity has increased by 22% YoY but it has decreased by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.